🇺🇸 FDA
Pipeline program

Olatorepatide

HS-20094-OB-2569

Phase 2 small_molecule active

Quick answer

Olatorepatide for Overweight or Obesity is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Overweight or Obesity
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials